BAX · CIK 0000010456
What Baxter International Inc. told the SEC could break it.
Baxter's disclosures revolve around a fragile materials supply chain for its medical products. It has had difficulty obtaining key inputs — electromechanical components, active pharmaceutical ingredients, and resins — and sources certain of them from single or sole suppliers, sometimes on a spot basis with no contract, where switching is slow and costly given FDA and global regulatory approval requirements. Those same sole-source relationships limit its ability to respond to tariffs, which already drove unfavorable manufacturing variances in its 2025 cost of sales. Adding a currency dimension, international sales were $5.12 billion of $11.24 billion (about 46%) in 2025, exposing it to translation and foreign economic and political risk.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Commodity & input dependence
- resins, pharmaceutical APIs, electromechanical componentsmedium
Baxter has faced and may face difficulties obtaining key materials — electromechanical components, active pharmaceutical ingredients, and resins — due to supply chain disruptions and shortages.
“We have faced, and may in the future face, difficulties obtaining supplies of key materials, such as electromechanical components, active ingredients for pharmaceuticals and resins, due to supply chain disruptions and global pandemics (including COVID-19).”
SEC filing →As of 2026
Regulatory & policy
- import tariffs (manufacturing cost impact)medium
Tariffs drove unfavorable manufacturing variances in Baxter's 2025 cost of sales, and its sole-source supplier relationships limit its ability to respond with alternative or lower-cost raw materials and components.
“Sole source supplier relationships may limit our ability to respond to these tariffs with alternative or lower cost raw materials or component parts.”
Sole-source dependency
- single/sole-source suppliers for key materialsmedium
Baxter sources certain raw materials and components from single or sole-source suppliers (some on a spot basis with no contract); replacing them may be slow and costly given FDA/global regulatory approval requirements.
“We acquire our components, raw materials, and other requirements for manufacturing from many suppliers and vendors in various countries, including sometimes from ourselves for self-supplied requirements. In certain instances, we use a single source or supplier or there is only a sole source or supplier.”
SEC filing →As of 2026
Currency (FX)
- international sales (~46% of net sales)low
International sales were $5.12 billion of $11.24 billion total (~46%) in 2025, exposing Baxter to currency translation and foreign economic/political risk across emerging markets and rest-of-world operations.
“Our global net sales totaled $11.24 billion in 2025, an increase of 6% over 2024 on a reported basis and 3% on an operational sales basis. International sales totaled $5.12 billion in 2025, an increase of 7% compared to 2024 on a reported basis and 5% on an operational sales basis.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Medline Industries
“In the United States, third parties, such as Cardinal Health, Inc. and Medline Inc., warehouse and ship a significant portion of our products through their distribution centers.”
Cited →“research and development effort through collaborations with other companies, such as our Integrated Table Motion product offering developed with Hillrom (now a part of Baxter International Inc.).”
Cited →“In the United States, third parties, such as Cardinal Health, Inc. and Medline Inc., warehouse and ship a significant portion of our products through their distribution centers.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch